Cargando…

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma

Mapatumumab and lexatumumab (targeting death receptor 4 (DR4) and 5 (DR5), respectively) are agonistic TRAIL receptor antibodies that induce apoptosis in a wide range of cancer cells. The potency of mapatumumab and lexatumumab was assessed in mono therapy protocols, and the ability to sensitize for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engesæter, Birgit, Engebraaten, Olav, Flørenes, Vivi Ann, Mælandsmo, Gunhild Mari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447808/ https://www.ncbi.nlm.nih.gov/pubmed/23029050 http://dx.doi.org/10.1371/journal.pone.0045492

Ejemplares similares

hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
por: Fleten, Karianne G, et al.
Publicado: (2016)

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
por: Belyanskaya, Larisa L, et al.
Publicado: (2007)

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
por: Magnussen, Gry Irene, et al.
Publicado: (2015)

Soluble AXL as a marker of disease progression and survival in melanoma
por: Flem-Karlsen, Karine, et al.
Publicado: (2020)

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
por: Slipicevic, Ana, et al.
Publicado: (2012)

AXL inhibition improves BRAF-targeted treatment in melanoma
por: Nyakas, Marta, et al.
Publicado: (2022)

Synergistic inhibitory effects of the oxyresveratrol and dacarbazine combination against melanoma cells
por: Lee, Sang Gyu, et al.
Publicado: (2021)

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
por: Maelandsmo, G. M., et al.
Publicado: (1996)

Aldehyde Dehydrogenase (ALDH) Activity Does Not Select for Cells with Enhanced Aggressive Properties in Malignant Melanoma
por: Prasmickaite, Lina, et al.
Publicado: (2010)

The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
por: Slipicevic, Ana, et al.
Publicado: (2008)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
por: Seip, Kotryna, et al.
Publicado: (2016)

p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
por: Flem-Karlsen, Karine, et al.
Publicado: (2019)

Reactive Oxygen Species Is Essential for Cycloheximide to Sensitize Lexatumumab-Induced Apoptosis in Hepatocellular Carcinoma Cells
por: Zhao, Xiangxuan, et al.
Publicado: (2011)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Dacarbazine nanoparticle topical delivery system for the treatment of melanoma
por: Hafeez, Abdul, et al.
Publicado: (2017)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Differential In Vivo Tumorigenicity of Distinct Subpopulations from a Luminal-Like Breast Cancer Xenograft
por: Skrbo, Nirma, et al.
Publicado: (2014)

Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
por: Øverbye, Anders, et al.
Publicado: (2017)

Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells
por: Pei, Junxia, et al.
Publicado: (2023)

Correction: Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells
por: Pei, Junxia, et al.
Publicado: (2023)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy
por: Xiong, Wei, et al.
Publicado: (2022)

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases()
por: Flørenes, Vivi Ann, et al.
Publicado: (2019)

Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions
por: Marini, Patrizia, et al.
Publicado: (2009)

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
por: Normann, Lisa Svartdal, et al.
Publicado: (2023)

Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line
por: Piotrowska, Anna, et al.
Publicado: (2019)

Co-delivery of Dacarbazine and All-Trans Retinoic Acid (ATRA) Using Lipid Nanoformulations for Synergistic Antitumor Efficacy Against Malignant Melanoma
por: Li, Chenyang, et al.
Publicado: (2020)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
por: Flørenes, Vivi Ann, et al.
Publicado: (2015)

Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
por: Moestue, Siver A, et al.
Publicado: (2010)

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013)

Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma
por: Yang, Chunhua, et al.
Publicado: (2016)

miR 204-5p inhibits apoptosis in dacarbazine-treated melanoma cells
por: PALKINA, NADEZHDA, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r753f9r0gckseosfugn1q5tlr9